All News

PIC/S membership accelerating international interest with market forecast to reach US$115bn by 2024.

Kisqali plus letrozole showed treatment benefit across all patient subgroups regardless of disease burden or tumour location.

The Xelum platform combines dosing, mixing, granulating and pressing, paving the way for more efficient tablet manufacturing.

Cinryze is the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics.

Nowadays, efficient process research and development are, more than ever, an absolute must for contract manufacturers and API manufacturers. New products/processes need to be pushed through to market readiness faster and faster. However, development de...

Welcome to visit us at booth 802 during CPhi Russia 2017 on Mar.28-30.

Only anti-PD-1 therapy approved for the treatment of patients with difficult-to-treat cHL regardless of prior stem cell transplantation or use of brentuximab vedotin

Supports small molecule ion channel drug discovery, from initial screening to development candidate.

For success in the biosimilars sector, manufacturers must adopt QbD, DoE and PAT initiatives.

Alliance brings together eye care and CRISPR innovators to develop transformative medicines for patients.

Zavicefta treat complicated infections caused By Gram-negative bacteria.

Dietary supplement products "misbranded" and unapproved new drugs being marketed with drug claims despite not being approved for any use.

Current product portfolio includes a range of specialty alkoxide bases and borane derivatives.

Together with Oxaliplatin and Folinic Acid, 5-FU is used in the most successful first line treatment of colon cancer (FOLFOX). As a second line treatment, it is successfully applied with Folinic Acid and Irinotecan (FOLFIRI). We can provide all these o...

With DCS Pharma your registration will be smooth because we have the most reliable source available, with complete documentation for regulated markets and full regulatory support.

Settlement provides Mylan with global licenses for its trastuzumab product.

Data suggest an alternative option for patients.

parodontax - first toothpaste proven to help consumers leave bleeding gums behind.

BI 836858 was previously granted orphan drug designation for the treatment of patients with AML.

Work on a second-generation fusion protein due to start in 2017 at Patheon's manufacturing facility in Brisbane.

The tablets are indicated for the treatment of major depressive disorder.

Collaboration is the second to evaluate a combination of CV301 with a checkpoint inhibitor.

Q Laboratories, Inc. (Cincinnati, Ohio) has added another tool to their microbial identification capabilities by acquiring the Bruker MALDI Biotyper®. This technology allows for rapid, cost-effective, accurate identification of thousands of microorgani...

Tooling products focused on increasing productivity for the tablet manufacturer.

Partnership formed to evaluate the impact of Amplycell’s novel cell fitness technology on expression capacity of Horizon’s bioproduction cell line.

Expansion plan comprises company's largest investment in the US.

The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.

He succeeds Dr Francis Cuss, 62, who will retire from the company.

Application seeks to expand Vraylar label to include Phase III clinical data for the maintenance treatment of schizophrenia.

Expanded week of dedicated sessions and trends on the world’s second largest pharma market.

Easy scale-up with Pharmatec pilot fermenter.

Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin.

Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.

Provides hope for patients with severe asthma, who currently have very limited treatment options.

Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

Represents Biocad's third authorized medicine for the treatment of relapsing-remitting multiple sclerosis.

Alcami will use the D8 DISCOVER HTS to add XRD capabilities to their laboratory service portfolio.

Merck's €42 million investment expands the allergies business on a global scale.

MEDI8897 has been engineered to have a long half-life so that only one dose would be needed for the entire RSV season.

More patients now able to receive a standard-of-care treatment with Erbitux plus Folfiri or Folfox.

Reinforces position as a supplier of excipients and raw materials for the pharmaceutical and biopharmaceutical industries.

Funding will be used to prepare for international clinical study to evaluate the Company’s ELISA-based urine test for prostate cancer.

Affinivax’s MAPS vaccine technology overcomes the limitations of current conjugate vaccine technology, creating a MAPS pneumococcal vaccine that enables broader protection.

Government plans to construct 10 factories for the manufacturing of biosimilars by 2020, with an additional investment of $265.3 million.

CPHI Middle East & Africa is a natural progression and rebrand of the rapid growth seen at CPHI Istanbul.

Acquisition enhances Lilly's existing pain management.

Second Biologics License Application accepted by the FDA for avelumab.

Innovation is being driven increasingly by smaller, possibly more agile, companies.

Supports a wide range of needs across the biopharma development cycle.

New model incorporates an improved algorithm to simplify test creation and accelerate test completion.

Partnership leverages Lonza's expertise in large-scale mammalian cell culture facilities alongside Sanofi's strength in developing and launching biologics based treatments.

If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment.

If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation.

Recall due to potential lack of sterility assurance.

Compared with warfarin, Pradaxa was associated with a 26% reduced risk of stroke and a 20% reduced risk of major bleeding.

Tool explores the time course of drug exposure, biomarker response and outcome.

Antibody levels maintained against multiple targets 6 months post vaccination.

Portfolio includes treatments for Crohn's disease, ulcerative colitis, and bowel preparation before endoscopy.

Approval of the automated mini-doser marks first hands-free administration option for a PCSK9 inhibitor in Europe.

Experimental vaccine targets mosquito saliva.

Aids R&D initiatives to advance precision medicine.

Modified baker’s yeasts cause an immune response and the production of lymphocyte killers, which detect and eliminate cancerous cells.

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016.

New kit enables covalent conjugation of antibodies and proteins to magnetic particles.

The acquired business is now known as Recipharm Pharmaservices Private Ltd.

Distributors, API manufacturers, and machinery providers seeing high demand across Russia and CIS.

Trial data further supports the existing clinical profile of CT-P13 in inflammatory bowel disease.

Unique sensor technology tracks inhalation profiles and technique.

Sartorius is offering its expertise to enhance scientific education and practice.

Study showed that people whose disease expressed PD-L1 and were treated with Tecentriq plus Avastin had a 36% reduction in the risk of their disease worsening

Company achieves the £9 million calendar year royalty cap on net sales of Ellipta products a year earlier than previously guided.

Steroid-free Spiriva Respimat now approved as asthma treatment for age 6 and older.

Expands softgel development and manufacturing capabilities and capacity.

The proposed biosimilar to Neulasta is used to reduce the duration of neutropenia and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer.

More than 50% of patients in three clinical studies who used Siliq achieved total skin clearance within a year.

Investment in a inductively coupled plasma mass spectrometry system is a move to address the updated ICH Q3D regulatory guidelines on elemental impurities.

Trends include ‘human factor’ principles, with ‘individualised packaging and serialisation’ as the integral solutions of the future.

Generic Pharmaceutical Association becomes Association for Accessible Medicines.

Complidermol 5α PLUS tackles not only the known hormonal factor, but also the oxidative and inflammatory factors, new pathophysiological factors identified as causes of this condition.

Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU.

The presentations highlight Alzheon’s ‘precision medicine’ approach to drug development for Alzheimer’s disease.

Acquisition paves the way for Quotient to replicate its Translational Pharmaceutics platform in America.

If approved, this treatment could be the first two-drug regimen for HIV.

Aker BioMarine has commissioned a new environmentally-friendly krill fishing vessel for NOK 1 billion. The vessel will be constructed in Norway by VARD

Symbiosis Pharma now able to offer East and West Coast clients small-scale aseptic manufacturing capabilities to support clinical trials.

Easyhaler is a dry powder inhaler for the treatment of asthma and COPD.

The Expanding role of pharmacovigilance in rapidly changing regulatory and commercial climates.

Foresee technology can help to develop stable, formulated peptides in solution for controlled-release therapy for 3- and 6-month durations of action after a single injection.

NIH-funded research suggests zebrafish models may be efficient resource for identifying drugs for clinical use.

Favourable macro trends will be reflected at CPHI South East Asia where domestic manufacturers are increasingly attending the event, with a view to opening up sales in international markets.

JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor.

The initial US$1.3 million order is to supply components for ultra low temperature robotic storage systems in the US to major pharmaceutical companies.

In the first video in our new series; Pharma Explained, Francess Zipp of Lachman Consultants explains why Good Manufacturing Practices (GMPs) are important and how a strong quality risk management system can ensure adherence to the GMPs.

PharmaCote ECxtra has been developed to stop the issues encountered by hard chrome, but still provide a coating that provides excellent tooling protection.

Praluent continues to be available to patients in the US.

Boehringer Ingelheim to conduct trial in collaboration with a subsidiary of Merck (MSD).

NIH-funded preclinical study suggests a possible treatment for Alzheimer’s disease and other neurodegenerative disorders.

Partnership to explore and identify new tools and methods to modify and optimize the CHO cell line performance.

IDT expands its capacity for direct sales of genomic products in Asia-Pacific region.

GSK launches Flonase Sensimist allergy relief nationwide.

Trulicity is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist injectable prescription medicine.

Intravenous administration puts delivery in hands of healthcare provider.

Company to introduce its portfolio of generics in France.

Vial injector, pharma compliance pack, smart packaging and autoinjector for prefilled syringes named best innovations in 2017.

The partnership will integrate Genedata Screener software with TTP Labtech’s acumen Cellista and mirrorball to improve screening data management.

Personal medical device leveraging "Internet of Things" technologies to address medication adherence.

By the end of 2017, company plans to increase to 230 process chemists and 70 analytical chemists.

Landmark Repatha cardiovascular outcomes study meets primary and key secondary endpoint.

Acquisition of Extrakt Chemie and site investments in people, equipment, manufacturing buildings and new offices increases company's position in Germany.

The growing number of states and countries getting approval for using marijuana in therapeutic applications is a crucial factor driving the demand over the coming few years.

Keytruda also receives Breakthrough Therapy Designation for second-line treatment.

A team of industry experts reward Nemera’s autoinjector with a Pharmapack Award as best innovation product.

Opdivo has now been approved in six tumour types in just over 2 years.

It is our pleasure to inform you that We Pharmaffiliates will be present in CPhI Istanbul 2017 which is being held at Istanbul, 8-10 March 2017. We will be open to meet all the Pharmaceutical Technocrats & Commercials and to discuss ...

It is our pleasure to inform you that We Pharmaffiliates will be present in CPhI North America 2017 which is being held at Philadelphia, 16-18 May 2017. We will be open to meet all the Pharmaceutical Technocrats & Commercials and to ...

The company’s growth has been driven by export, with a three-fold increase in activity outside of the UK during 2016,

Rentschler will become the first and only CDMO to have access to Leukocare's patented SPS formulation technologies.

Acquisition provides fully equipped facilities for the development and manufacture of clinical stage cellular therapy products, including three ISO7 cGMP manufacturing suites, extensive flow cytometry and analytical infrastructure.